In Vitro Efficacy of Antibiotic Combinations with Carbapenems and Other Agents against Anaerobic Bacteria
- PMID: 35326756
- PMCID: PMC8944673
- DOI: 10.3390/antibiotics11030292
In Vitro Efficacy of Antibiotic Combinations with Carbapenems and Other Agents against Anaerobic Bacteria
Abstract
We investigated the in vitro efficacy of combinations of carbapenems with clindamycin (CLDM) and minocycline (MINO) against Bacteroides fragilis and Peptostreptococcus species. We selected the carbapenems imipenem, meropenem, panipenem, doripenem, and biapenem. To evaluate the antibiotic efficacy of these combination regimens, the fractional inhibitory concentration index (FICI) was calculated against clinical isolates. Consequently, combination regimens of each carbapenem with CLDM or MINO showed synergistic or additive effects against 83.3−100.0% and no antagonistic effects against P. anaerobius isolates. However, against the B. fragilis group (B. fragilis, B. thetaiotaomicron, and Parabacteroides distasonis), although the combination with other carbapenems and CLDM or MINO did not show remarkable synergistic effects, the combination regimen of IPM with CLDM or MINO indicated mainly additive antibiotic efficacies (FICIs: >0.5 to ≤1.0) to B. fragilis groups. Then, antagonistic effects were admitted in only 5.6% of B. fragilis groups. The effectiveness of antibiotic combination therapy against pathogenic anaerobes has remained unclear. Then, our results can provide new insights to explore the effective combination regimens against multidrug-resistant anaerobic bacteria as empirical and definitive therapies, while this study used only carbapenem susceptible isolates. Hence, further studies are needed to use highly antibiotic-resistant anaerobic isolates to carbapenems.
Keywords: Bacteroides; Peptostreptococcus; carbapenem; checkerboard assay; clindamycin; combination therapy; minocycline.
Conflict of interest statement
Hiroshige Mikamo received grant support from Shionogi & Co., Ltd.; Daiichi Sankyo Co., Ltd.; FUJIFILM Toyama Chemical Co., Ltd.; Sumitomo Dainippon Pharma, Co., Ltd.; ASAHI KASEI PHARMA CORPORATION.; and Pfizer Japan Inc., and payment for lectures from MSD K.K.; FUJIFILM Toyama Chemical Co., Ltd.; Miyarisan Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Pfizer Co., Ltd.; Astellas Pharma Inc., Sumitomo Dainippon Pharma, Co., Ltd.; and Becton, Dickinson and Company.
Figures
Similar articles
-
In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.Antimicrob Agents Chemother. 2013 Jun;57(6):2620-30. doi: 10.1128/AAC.02418-12. Epub 2013 Mar 25. Antimicrob Agents Chemother. 2013. PMID: 23529731 Free PMC article.
-
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104. Mikrobiyol Bul. 2014. PMID: 24819268 Turkish.
-
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.Antimicrob Agents Chemother. 2008 Sep;52(9):3161-8. doi: 10.1128/AAC.00355-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625771 Free PMC article.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
-
Carbapenem resistance in Bacteroides fragilis: A review of molecular mechanisms.Anaerobe. 2022 Aug;76:102606. doi: 10.1016/j.anaerobe.2022.102606. Epub 2022 Jun 20. Anaerobe. 2022. PMID: 35738484 Review.
Cited by
-
Advances in drug resistance and resistance mechanisms of four colorectal cancer-associated gut microbiota.PeerJ. 2025 Jun 10;13:e19535. doi: 10.7717/peerj.19535. eCollection 2025. PeerJ. 2025. PMID: 40520636 Free PMC article. Review.
References
-
- Ali S., Dennehy F., Donoghue O., McNicholas S. Antimicrobial susceptibility patterns of anaerobic bacteria at an Irish Uni-versity Hospital over a ten-year period (2010–2020) Anaerobe. 2021;7344:102497. - PubMed
LinkOut - more resources
Full Text Sources